@Article {Wong1902222，作者= {Wong，Aaron和Zamel，Ricardo和Yeung，Jonathan和Bader，Gary D.和Dos Santos，Claudia C.和Bai，Xiaohui和Wang，Yubo和Keshavjee，Shaf和Liu，Mingyao}，标题= {人类前体内肺灌注期间肺修复的潜在治疗靶标}，Elocation-Id = {19022222}，年= {2020}，DOI = {10.1183 / 13993003.02222-2019}，出版商= {欧洲呼吸社会}，摘要188bet官网地址= {介绍前体内肺灌注（EVLP）技术已经开发出来评估边缘供体肺的功能，这些供体肺利用率显着增加。EVLP还通过损伤特异性治疗等抗生素或纤维蛋白溶解剂如抗生素或纤维蛋白溶解剂探索的平台。我们假设移植和EVLP之间的积极表达途径可揭示移植前肺部修复损伤和潜在治疗靶标的常见机制。材料和方法在脑死后捐赠的外周组织活组织检查进行回顾性转录组科分析{\ textquotedblright}肺部，有46个前/后移植双/ evlp对的49对。途径分析用于鉴定和比较供体肺部对移植和EVLP的反应。结果二十一条途径主要在移植中富集，包括淋巴细胞活化和细胞死亡的上调，以及代谢和蛋白质合成的下调。七种途径主要在EVLP中富集，包括下调白细胞功能和血管过程的上调。通常富集二十三种途径，包括激活先天炎症，细胞死亡，热应激和代谢下调。在炎症簇中，TLR / MYD88信令具有最多的节点，并且炎症是炎症的核心。这些机制先前已经推测为动物模型中急性肺损伤的主要机制。结论EVLP和移植份额常见的损伤分子特征，包括天生的炎症和细胞死亡。 Blocking these pathways during EVLP may allow for lung repair prior to transplantation.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Wong has nothing to disclose.Conflict of interest: Dr. Zamel has nothing to disclose.Conflict of interest: Dr. Yeung has nothing to disclose.Conflict of interest: Dr. Bader has nothing to disclose.Conflict of interest: Dr. Dos Santos has nothing to disclose.Conflict of interest: Dr. Bai has nothing to disclose.Conflict of interest: Dr. Wang has nothing to disclose.Conflict of interest: Dr. Keshavjee has nothing to disclose.Conflict of interest: Dr. Liu has nothing to disclose.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2020/02/26/13993003.02222-2019}, eprint = {//www.qdcxjkg.com/content/early/2020/02/26/13993003.02222-2019.full.pdf}, journal = {European Respiratory Journal} }